Detection of HPV types and neutralizing antibodies in Gansu province, China

Abstract

A total of 82 samples from patients with cervical cancer (Group 1) and 50 samples from patients with other genital diseases (Group 2) were collected in Gansu, China. All 132 samples were tested for HPV DNA with a typing kit that can detect 21 types of HPV, and also tested for neutralizing antibodies against HPV-16, -18, -58, -45, -6, and -11 using pseudovirus-based neutralization assays. The results revealed that 28% (23/82) of sera in Group 1 were positive for type-specific neutralizing antibodies with a titer range of 160-640, of which 23.2% (19/82), 2.4% (2/82), 2.4% (2/82), 1.2% (1/82), and 1.2% (1/82) were against HPV-16, -58, -6, -18, and -45, respectively. Only one serum (2%) in Group 2 was positive for neutralizing antibodies, which were against HPV-6 with a titer of 2,560. Overall, 85.4% (70/82) of samples in Group 1 were HPV DNA-positive, compared with 28% (14/50) of samples in Group 2. The seven most common types detected in Group 1 were HPV-16 (80%), HPV-52 (7.1%), HPV-66 and HPV-11 (5.7% each), and HPV-58, HPV-18, and HPV-33 (4.3% each), while the four most common types in Group 2 were HPV-16 (12%), HPV-52 and HPV-11 (6% each), and HPV-68 (4%). The concordance between HPV DNA and corresponding neutralizing antibodies was 32.9% (27/82) with a significant difference (P < 0.005). More specifically, the concordance was 42.7% (35/82) for HPV-16 in Group 1. The full-length sequences of six HPV types (HPV-16, -58, -33, -59, -11, and -68) were determined and showed 99% identities with their reported genomes.

Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or high‐grade precancerous lesions in Chengdu, western China

“…The prevalence of HPV infection among patients with cervical carcinoma varies from 70% to 93% in different regions of China [7,8,10,11]. According to a recent meta-analysis, the prevalence of HPV infection in cervical cancer and high-grade precancerous lesions in China was 83.7% and 66.2%, respectively [12].…”

Human Papillomavirus (HPV) L1 and L1-L2 Virus-Like Particle-Based Multiplex Assays for Measurement of HPV Virion Antibodies

“…HPV seropositivity is higher in cervical cancer patients than in controls, and seropositivity has been associated with other HPV-related cancers (5). In the general population, studies are conflicting as to whether naturally acquired antibodies protect against infection (16,21,24,31). A major challenge of using serostatus as a measure of past or current infection is that not all infected individuals seroconvert (4,17,30), and seropositivity is higher in females than males (21).…”

“…Neutralizing antibodies to HPV16 and -18 were separately measured using PsV-based neutralization assays developed in the laboratory of John Schiller at the NCI (29) and used in a number of epidemiologic investigations (26,27,30,31). Purified pseudovirion stocks were titrated to determine the minimum concentration needed to detect SEAP activity following infection of 293TT cells.…”

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences

“…LN833161 to LN833190) and 48 complete genomes available in GenBank (GenBank accession no. EU918768 [30]; FR872717 [31]; FN870021, FN870022, and FN907957 to FN907964 [25]; JQ773408 to JQ773412 [32]; HE574701 to HE574705 [19]; JN644141 [33]; and HE611258 to HE611274, HE962023 to HE962025, and HE962365 to HE962368 [34]), including the sequence with PaVE accession no. HPV11REF.…”